FindTrial
Sign In

Usefulness of lignocaine medicated pad for reducing pain in patients during administration of Rabies immunoglobulin (RIG)

Effectiveness of 2% lignocaine medicated pad for reducing pain in patients during administration of Rabies immunoglobulin (RIG)

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2018/02/011803
Enrollment
100
Registered
2018-02-09
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Adult Patients (18 to 60 yrs) coming to the Preventive Clinic of Medical College, Thiruvananthapuram with Category III animal bites in whom Rabies Immunoglobulin is given

Interventions

Intervention1: 2% Lignocaine medicated pad: The procedure shall be done after administering the test dose of ERIG, so as to allow at least 20 minutes of contact with the local anaesthetic. Patient wi

Sponsors

State Board of Medical Research
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Adult Patients (18 to 60 yrs) coming to the Preventive Clinic of Medical College, Thiruvananthapuram with Category III animal bites in whom Rabies Immunoglobulin (Equine Rabies immunoglobulin/Human Rabies Immunoglobulin) is adviced, with minimum 2 wounds on two different sites. Persons with more than 2 wounds will also be recruited and the most proximal and distal wound shall be taken for the study. One wound will be randomized to the intervention and the other to the placebo arm. Proximal wound is the wound closest to head and distal wound will be the one farthest from the head. In case of a wound on the face, proximity to an imaginary line drawn through the middle of the nose will be considered.

Exclusion criteria

Exclusion criteria: Those who are not giving consent Known Allergic to Lignocaine History of contact dermatitis Those with any contraindications to lignocaine All mucosal exposures

Design outcomes

Primary

MeasureTime frame
Pain measured by the following Visual Analog Scale Verbal Rating scale Observed pain-motor â?? by using the scale used by Wright, given in table 1. The procedure will be videotaped using a good quality mobile camera and evaluated independently by two experts to rate the scale Timepoint: During the administration of Rabies immunoglobulin—

Secondary

MeasureTime frame
Overall heart rate change â?? Difference between Heart rate at baseline (recorded while taking history and Heart rate during the administration of RIG)Timepoint: 20 minutes after—

Countries

India

Contacts

Public ContactZinia T Nujum

Government Medical College, Kollam

drzinia@gmail.com9037356908

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026